Stago Offers Three Procoagulant Microparticle Detection Methods

January 4, 2012, Parsippany, NJ, USA – Diagnostica Stago announces three new products to suit a variety of clinical research needs for procoagulant and total microparticle detection. Microparticles are tissue factor-bearing phospholipid vesicles that have often been the subject of clinical research studies into various conditions such as cancer, diabetes, sickle cell disorder, as well as parasitic and viral infections. Research into this topic is currently expanding rapidly, with many studies being communicated frequently at scientific meetings.
Stago Offers Three Procoagulant  Microparticle Detection Methods

Megamix uses flow cytometry for multi-parameter quantification and standardization of total microparticle detection. This method uses three microparticle sizing beads to optimize microparticle detection, and also allows subset identification and vesicle size measurement. When paired with cell-specific antigen analysis, this method allows for determination of the cell of origin of the microparticle.  Peer-reviewed publications reporting the use of Megamix in research applications are publicly available.

The STA®-Procoag PPL clotting assay provides functional measurement of procoagulant phospholipids such as microparticles in multiple sample types. As no sample dilution or washing steps are required, the assay allows for microparticle functional analysis in a manner most similar to the physiological conditions. This method is bar-coded and is adaptable to the STA line of automated coagulation analyzers for the purpose of larger clinical studies, and is insensitive to heparin within therapeutic ranges.

Finally, the MP reagent for the Calibrated Automated Thrombogram® instrumental platform is standardized for use on that platform and utilizes a thrombin generation readout to continuously measure functional procoagulant microparticle levels. Sub-sampling and plasma defibrination are not necessary, and the assay is scaleable for medium-throughput research applications.

All three procoagulant microparticle detection platforms are labeled for research use only, and are not for use in diagnostic procedures worldwide.

 

About Diagnostica Stago, Inc.

Diagnostica Stago, Inc. is the exclusive provider of the Diagnostica Stago Hemostasis product lines in the United States and offers a complete system of coagulation instruments and optimized reagent kits for research as well as for routine analysis. Diagnostica Stago, Inc. is the U.S. subsidiary of Diagnostica Stago, S.A.S. France, a leader in the development and manufacture of Hemostasis products. For more information about any Stago product or service, please call 800-222-COAG or visit our website at Opens external link in current windowwww.stago-us.com.

 

Contacts:

Paul Riley, PhD, Manager, Research Use Products
Diagnostica Stago, Inc.
(973) 631-1200 x4238
Ouvre une fenêtre pour la rédaction d'un mailpaul.riley@stago-us.com